



# HIVR4P 2024

## Satellite

Sunday, October 6, 2024, 10:30 - 12:00

## Link:

<https://programme2024.hivr4p.org/>

## Session Details:

Sunday, October 6, 2024, 10:30 - 12:00



## SATELLITE SYMPOSIA

**ORGANIZER: BRIC-TRANSLATIONAL  
HEALTH SCIENCE AND TECHNOLOGY  
INSTITUTE (THSTI), INDIA**

**A compelling armour in  
the diverse toolbox:  
The promise of broadly  
neutralizing antibodies  
as HIV prevention  
options in times of  
globally evolving viral  
variants**



**SAT 13  
LIMATAMBO 2/CHANNEL 2**



**SUNDAY, 6 OCTOBER, 2024  
10:30 - 12:00**



**Department of Biotechnology  
Ministry of Science & Technology  
Government of India**



## CHAIR & MODERATOR



**DR. GEORGIA  
TOMARAS**  
Duke University, USA

## THE SPEAKER LINEUP



**DR. PENNY MOORE**  
The National Institute  
for Communicable  
Diseases, South Africa



**DR. JAYANTA  
BHATTACHARYA**  
BRIC-THSTI, India



**DR. VINCENT  
MUTURI KIOI**  
International AIDS  
Vaccine Initiative,  
Kenya



**DR. TORBEN  
SCHIFFNER**  
Scripps Research,  
USA



**DR. GUIDO  
FERRARI**  
Duke University,  
USA



**Topic:**

**A compelling armour in the diverse toolbox: The promise of broadly neutralizing antibodies as HIV prevention options in times of globally evolving viral variants**

The enormous diversity of the globally circulating variants of HIV-1 has posed a significant challenge towards developing effective prevention modality. In the absence of a preventive vaccine, highly active antiretroviral (ARV) based therapy has been the only treatment option that is available for people living with HIV/AIDS. Although ARVs have been very effective, however in concurrence with the periodic evolution of the HIV globally, drug resistance and treatment failure has become a major concern. Broadly neutralizing monoclonal antibodies (bnAb) have shown as a promising approach towards prevention of viral infection and are being considered as an alternate for prevention from HIV acquisition in the absence of an effective vaccine. Recent findings from the Phase 2B HVTN 703/HPTN 081 Antibody-Mediated-Prevention-Trial (AMP clinical) have indicated potentially transformative bnAb mediated prophylaxis strategies.

BRIC-Translational Health Science and Technology Institute (THSTI), India along with the THSTI-IAVI Antibody Translational Research Program is organizing a satellite session where leading scientists from Africa, India and USA will present some of the key observation and advancements made in this field highlighting some of the promising approaches for bnAb mediated HIV-1 prevention. The session will cover insights on (a) suitability of lead bnAbs against globally circulating contemporary HIV with particular reference to clade C, (b) effectivity of bnAbs for infant prophylaxis particular in high disease burden areas, their clinical impact and cost effectiveness, (c) advances in germline targeting approaches in eliciting broadly neutralizing antibodies and (d) modalities to enhance antibody effector function.

**Organizing institute:**

BRIC-Translational Health Science and Technology Institute (THSTI), India

**Organizers:**

Dr Ganesan Karthikeyan (THSTI, India)

Dr Jayanta Bhattacharya (THSTI, India)